Pluristem Therapeutics Inc. (PSTI) Director Mark Germain Sells 23,818 Shares

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Director Mark Germain sold 23,818 shares of Pluristem Therapeutics stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $1.50, for a total transaction of $35,727.00. Following the transaction, the director now directly owns 559,817 shares in the company, valued at $839,725.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mark Germain also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 16th, Mark Germain sold 45,873 shares of Pluristem Therapeutics stock. The stock was sold at an average price of $1.48, for a total transaction of $67,892.04.

Shares of NASDAQ:PSTI opened at $1.24 on Friday. Pluristem Therapeutics Inc. has a fifty-two week low of $1.06 and a fifty-two week high of $2.12.

A number of equities analysts have issued reports on the stock. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Thursday, March 15th. Maxim Group set a $3.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 21st. Finally, ValuEngine downgraded shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Pluristem Therapeutics has a consensus rating of “Hold” and an average price target of $3.38.

Large investors have recently modified their holdings of the stock. Meitav Dash Investments Ltd. purchased a new position in shares of Pluristem Therapeutics in the 4th quarter worth about $138,000. Psagot Investment House Ltd. boosted its holdings in shares of Pluristem Therapeutics by 1,705.2% in the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after buying an additional 122,347 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Pluristem Therapeutics by 363.5% in the 4th quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock worth $401,000 after buying an additional 228,149 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Pluristem Therapeutics by 15.0% in the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after buying an additional 34,742 shares during the last quarter. 4.20% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/pluristem-therapeutics-inc-psti-director-mark-germain-sells-23818-shares-of-stock.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply